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Epidemiological changes in meningococcal
meningitis in Niger from 2008 to 2011 and the
impact of vaccination
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Muhamed-Kheir Taha5, Brian Greenwood6 and Jean-François Jusot1
Abstract
Background: The epidemiology of bacterial meningitis in the African ‘meningitis belt’ changes periodically. In order
to design an effective vaccination strategy, we have examined the epidemiological and microbiological patterns of
bacterial meningitis, and especially that of meningococcal meningitis, in Niger during the period 2008–2011. During
this period a mass vaccination campaign with the newly developed meningococcal A conjugate vaccine
(MenAfriVac®) was undertaken.
Method: Cerebrospinal fluid samples were collected from health facilities throughout Niger and analysed by
culture, seroagglutination and/or speciation polymerase chain reaction, followed by genogrouping PCR for Neisseria
meningitidis infections. A sample of strains were analysed by multi-locus sequence typing.
Results: N. meningitidis serogroup A cases were prevalent in 2008 and 2009 [98.6% and 97.5% of all N. meningitidis
cases respectively]. The prevalence of serogroup A declined in 2010 [26.4%], with the emergence of serogroup W
Sequence Type (ST) 11 [72.2% of cases], and the serogroup A meningococcus finally disappeared in 2011. The
geographical distribution of cases N. meningitidis serogroups A and W within Niger is described.
Conclusion: The substantial decline of serogroup A cases that has been observed from 2010 onwards in Niger
seems to be due to several factors including a major polysaccharide A/C vaccination campaign in 2009, the
introduction of MenAfriVac® in 10 districts at risk in December 2010, the natural dynamics of meningococcal
infection and the persistence of serogroup A sequence-type 7 for about 10 years. The emergence of serogroup W
strains suggests that there may be a need for serogroup W containing vaccines in Niger in the coming years.
Keywords: Neisseria meningitidis serogroup A and W, Meningitis, Niger, Vaccination, MenAfriVac®, Sequence-type
lineage evolution, Immunization
Background
Neisseria meningitidis (Nm) is responsible for frequent
outbreaks of meningococcal meningitis in the African
‘meningitis belt’, a sub-Saharan zone which stretches
from Ethiopia to Senegal. Epidemics show marked sea-
sonality, peaking during the dry, hot season [1] and they
can cause many deaths (mortality around 10%) and re-
sidual disability. During major epidemics, attack rates
can range from 100 to 800 per 100 000 population.
Nm serogroup A (Nm A) is the main cause of epi-
demics in Africa. However, serogroup C was responsible
for epidemics in Nigeria in the 1970s [2] and in Upper
Volta (now Burkina Faso) in the 1980s [3], serogroup W
sequence type (ST)-11 caused severe epidemics in Burkina
Faso in 2002 and 2003 [4,5], and serogroup X caused an
outbreak in Niger in 2006 [6]. A strategy of reactive
immunization with an anti-meningococcal A/C polysac-
charide vaccine has been used for many years to control
epidemics in the African meningitis belt, based on WHO
recommendations [7]. This approach has mitigated the ex-
tent of meningitis outbreaks but it has not prevented the
continuing occurrence of large outbreaks of the disease.
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The reactive vaccination strategy relies on early detection
of outbreaks followed by mass vaccination with a polysac-
charide vaccine adapted to the circulating serogroup, once
an incidence threshold has been crossed. Polysaccharide
vaccines provide only short-term protection in children
and have little or no impact on pharyngeal carriage [8]. A
newly developed meningococcal A conjugate vaccine,
MenAfriVac®, was introduced in 2010 in Burkina Faso,
Mali and Niger through mass vaccination campaigns di-
rected at those aged 1-29 years. Initial findings from
Burkina Faso and Chad suggest that this vaccine provides
some herd protection, by preventing pharyngeal carriage,
as well as protecting directly vaccinated individuals [9,10],
as seen following the introduction of a monovalent men-
ingococcal C conjugate vaccine in the United Kingdom
[11]. The aim of the MenAfriVac® programme is to elimin-
ate large meningitis outbreaks in the 26 most severely af-
fected countries of sub-Saharan Africa.
The purpose of the study reported here was to study
the circulation of Nm A and Nm W in Niger since 2008,
and to examine the current epidemiological situation in
relation to the availability of polysaccharide vaccines
against Nm W. We have also tried to correlate the
marked decrease in the number of cases caused by Nm
A, and the increased number due to Nm W, with data
on vaccination and to speculate on the evolution of
sequence-type lineages and naturally acquired immunity
in the study population.
Methods
Ethics statement
Cerebrospinal fluid (CSF) samples were collected from
patients with suspected meningitis by clinicians, with
the patient’s or their family’s oral consent, according to
the national guidelines for routine clinical care in Niger.
Aliquots of CSF remaining after routine CSF examin-
ation by health facilities for case management were sent
on a voluntary basis to the Centre de Recherche Médicale
et Sanitaire (CERMES) to meet the WHO guidelines of
enhanced microbiological surveillance of meningitis. Con-
fidentiality on patients’ identity was guaranteed.
Introduction of MenAfriVac®
MenAfriVac®, a meningococcal A (MenA) tetanus toxoid
conjugate vaccine, developed by the Meningitis Vaccine
Project (MVP) (http://www.meningvax.org/), was intro-
duced on a pilot scale in September 2010 in Niger (1 dis-
trict). The first district to be vaccinated was Filingué,
targeting 392,211 individuals aged 1-29 years (data from
the Direction of Surveillance and Response to Epidemics
(DSRE), Ministry of Public Health (MoPH), Niger). In
December 2010, MenAfriVac® was introduced on a larger
scale in Niger. Eight districts of the Tillabery and Niamey
Regions, and 2 districts from the Dosso Region were
vaccinated covering 3.1 millions of individuals. In 2011,
Niger completed the last phase of their own vaccination
campaigns (7.4 million individuals), boosting the total
number vaccinated to almost 10.9 million.
Epidemiological surveillance
Epidemiological surveillance in Niger is undertaken by
the Direction of Surveillance and Response to Epidemics
(DSRE), MoPH. Quantitative data on incidence and the
mortality per age class for all clinically suspected cases
of meningitis who meet a standard case definition are no-
tified weekly to the MoPH. This clinical surveillance is
coupled to microbiological surveillance performed by
CERMES using CSF samples collected throughout Niger.
Collection of CSF
In Niamey, between November and June (the meningitis
season), aliquots of CSF kept at room temperature after
routine CSF examination by national and regional hospi-
tals for case management were collected by CERMES.
Additionally, during the same period from 2003-2010,
frozen CSF samples were collected monthly by CERMES
from hospitals within a radius of 300 km from Niamey
(Dosso and Tillabéry Regions). This collection was
stopped at the time of the implementation of enhanced
case by case surveillance in 2011. Refrigerated or frozen
CSF samples, and occasionally CSF-inoculated trans-
isolates (TI), were sent on a voluntary basis to CERMES
or DSSRE by mandated transport companies from the
rest of the country.
Bacteriological and molecular analysis of CSF
Laboratory confirmation of meningococcal meningitis
was performed at CERMES using culture and/or PCR
techniques on CSF or TI as described previously [12].
CERMES provided information weekly to the DSRE on
the number of confirmed cases, their aetiology, sampling
date and geographical distribution to aid decisions on
epidemic control.
Multi-locus sequence typing
A representative sample of strains of N. meningitidis was
sent every year from 2002 to the WHO collaborative
centre (WHOCC) for the meningococcus in IMTSSA
(Marseille, France) for multi-locus sequence typing
(MLST). In 2011, strains were sent to the new WHOCC
for the meningococcus at the Pasteur Institute, Paris,
France. DNA-PCR-amplified fragments from seven
housekeeping genes (abcZ, adk, aroE, fumC, gdh, pdhC
and pgm) were sequenced and their allelic profiles com-
pared to the existing alleles available on the Internet
Multilocus sequence typing data bank (http://www.mlst.
net) to determine their sequence type [13].
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Data management and analysis
Descriptive statistics were used to describe the epidemi-
ology of meningococcal meningitis using both data from
epidemiological surveillance provided by the MoPH and
from microbiological surveillance performed by CERMES.
Results
Surveillance data
From 1st January 2008 to 31st December 2011, the MoPH
of the Republic of Niger reported a total of 22, 046 sus-
pected cases of meningitis with a case fatality rate (CFR)
of 5.7% (Table 1, Figure 1). A major epidemic in 2009
accounted for 63.2% of the total cases but this outbreak
had the lowest CFR (4.2%). Microbiologic analyses of all
CSF samples obtained during these four years are pre-
sented in Table 1 and shown on a weekly scale in Figure 2.
In the 2008 and 2009 meningitis seasons, a large majority
of meningococcal infections were due to Nm A (98.6%;
N = 1067 and 97.5% ; N = 1654 respectively). Nm W
emerged in 2010 (72.2% of isolates; N = 665) while the
percentage of Nm A isolates declined (26.4%; N = 243),
and in 2011 there was a strong predominance of Nm W
isolates (98.1%; N = 402) with only 5 isolates of Nm A.
The increase in Nm W meningitis cases was accompan-
ied by an increase in the CFR (from 6.7% and 4.2% re-
spectively in 2008 and 2009 to 12.2% in 2011). Two of
the five cases of Nm A meningitis detected in 2011 in
zones vaccinated with MenAfriVac® concerned young
males aged 12 and 25 years that had not been vacci-
nated. The other three cases came from districts where
MenAfriVac® had not been distributed at that time that
they became ill (Keita and Matameye in the central part
of the country and Agadez in the north). Nm X cases
were infrequent with only 22 PCR-positive CSF samples
obtained over the four-year period, 15 of which were de-
tected in 2009. Numbers of cases of Streptococcus pneu-
moniae meningitis remained relatively constant over the
observation period with 117, 78, 93 and 70 cases re-
spectively detected in 2008, 2009, 2010 and 2011 re-
spectively. Pneumococcal conjugate vaccination will be
introduced in Niger likely in 2015. Fifty-four percent (N =
5393) of CSF samples remained without a bacteriological
aetiology after culture and PCR.
The mean ages of confirmed cases of serogroup A men-
ingitis (N = 2969), and serogroup W meningitis (N =
1078), were 10.3 (SD = 7.8), and 8.9 (SD = 10.3) years
respectively (t-test = 3.95, df = 1490, p < 0.0001). The age
groups most affected were 5-9 years and 1-4 years for ser-
ogroups A and W respectively (Figure 3). The numbers of
serogroups A and W confirmed cases in those less than
2 years were 84 (2.97%) and 168 (16.28%), respectively.
MLST Molecular typing
Most of the Nm A strains analysed (N = 141) by MLST
during the 2002-2011 period belonged to ST-7 (N = 131;
92.9%) (Table 2), except for nine ST-2859 isolates (6 in
2007, 2 in 2008 and 1 in 2009) and one ST-5788 isolate
(obtained in 2006). The strains belonging to ST-2859 all
originated from Niamey, whereas the other ST-7 strains
were isolated from all parts of the country. Nm W strains
isolated in 2010 and 2011 (N = 30) and analysed by MLST
belonged to ST-11. NmW ST-11 strains were also isolated
in 2002 (N = 4) and 2003 (N = 5). From 2004 to 2009 all
NmW strains analysed were ST-2881 (N = 22).
Geographical analyses
A map of the Regions (or Departments) and Districts (or
Arrondissements) of Niger can be accessed at http://
commons.wikimedia.org/wiki/Atlas_of_Niger. Figure 4
shows the geographic extension and decline of Nm A in
Niger between 2008 and 2011, and the extension of
Nm W since 2010.
2008: Nm A cases, representing 98.6% of the total Nm
cases, were concentrated in the southern and central
Table 1 Results from the epidemiological and microbiological surveillance of meningitis in Niger (2008-2011)
Year Notified
cases
Deaths CFR CSF
collected
% CSF
collected/
declared
cases
Nm
(all types)
Nm A Nm W Nm X Other
serog.
Non-typ.
Nm
Spn Hi Other Negative
CSF
2008 3851 256 6.65 2716 70.5 1082 1067
(98.6%)
0 5 0 10 117 33 23 1461
2009 13943 589 4.22 3915 28.1 1696 1654
(97.5%)
11 15 1 (Y) 15 78 12 66 2063
2010 2908 251 8.63 2384 82.0 921 243
(26.4%)
665
(72.2%)
1 0 12 93 22 26 1322
2011 1344 164 12.20 1041 77.5 410 5 402
(98.1%)
1 0 2 70 2 12 547
Total 22046 1260 5.71 10056 45.6 4109 2969 1078 22 1 39 358 69 127 5393
Epidemiological data are from the Direction of Surveillance and Response to Epidemics (DSRE), Ministry of Public Health; Microbiological data from CERMES.
CSF, cerebrospinal fluid; Nm, Neisseria meningitidis, CFR, case fatality rate.
Spn, Streptococcus pneumoniae; Hi, Haemophilus influenzae.
‘Other’ are other aetiologies (i.e. Salmonella sp.), contaminated or broken samples.
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Figure 1 Attack rates of meningitis in Niger during the years 2008 to 2011 (data collected by the Direction of Surveillance and
Response to Epidemics – Ministry of Public Health).
Figure 2 Epidemic curves of confirmed N. meningitidis serogroups A (grey histograms) and W (black) cases on a weekly scale detected
from 2008 to 2011. Vaccinations with polysaccharide (PS) bivalent A/C and trivalent A/C/W vaccines are indicated (with the number of
administered doses). The three successive MenAfriVac® campaigns are also shown.
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parts of the country (Dosso, Tahoua, Maradi and Zinder
regions), along the border with Nigeria.
2009: Nm A cases dominated again (97.5%) with very
few cases of other serogroups (15 Nm X, 11 Nm W,
1 Nm Y, 15 non groupable (NG)-Nm) being detected
among 3915 CSF samples analyzed. Nm A cases were
spread over almost the whole country. During the epi-
demic season twenty-five of the 42 health districts had
an attack rate of suspected cases over 10/100,000/week
(epidemic threshold) and 11 districts an attack rate over
5/100,000/week (alert threshold). During the epidemic
peak, attacks rates reached values up to 33.4 and 27.6/
100,000/week in Madarounfa and Magaria districts
respectively.
2010: Nm A cases (26.4% of all meningococci) were
still distributed across almost all districts (32/42), but
the number of confirmed cases had decreased remark-
ably (N = 243) whereas Nm W cases increased dramatic-
ally in number (N = 665 cases; 72.2%) and were recorded
in 35/42 districts. Nm A cases were concentrated in the
western part of the country whereas the highest num-
bers of Nm W cases were observed in the southern and
central parts of the country (mainly in Maradi and
Madarounfa districts). To investigate the geographical dis-
tribution of the mixed epidemics of 2010, the distribution
of serogroups A and W by month by health centre catch-
ment area (HCCA) was determined. Figure 5 showed that
in January 2010, Nm W cases began to emerge in HCCA
of three districts, two located at the borders with Nigeria
and one located at the border with Burkina Faso. Nm A
cases were detected in HCCA of 11 districts. In February,
Nm A remained the predominant serogroup and cases
were present in HCCA of 12 districts whereas Nm W
spread to HCCA of 9 districts located in the centre of
Niger. In March, Nm W continued to be detected to the
Western and Eastern region of Niger while Nm A
remained predominant in HCCA of 10 districts located in
the Western part of the country. April 2010 showed a
clear predominance of Nm W in HCCA of 26 districts.
2011: Nm W cases (97.8%) were recorded predomin-
antly in the western and central parts of the country (ex-
cept for the district of Matameye). About 50% of the
Nm W cases originated from the region of Tillabery vacci-
nated with MenAfriVac® in December 2010. No cases were
reported from the eastern part of the country (Magaria,
Zinder, Tanout, Mirriah, Maine Soroa, Nguigmi and Diffa
districts) bordering Nigeria and Chad.
Vaccination
In 2008, in response to the epidemic, 146,854 doses of
polysaccharide (PS) A/C vaccine were administered in
the districts of Filingue and Say, with coverage of 52.4%
and 54.7% of the target population respectively.
In 2009, in response to the epidemic, but also to prevent
outbreaks in some districts considered at risk, PS A/C vac-
cines were used to immunize a total of 5,904,978 subjects
across the whole country with a vaccination coverage
(mean per district) of 52.4% ±39% for the target
Figure 3 Age groups affected by N. meningitidis serogroups A (N = 2964) and W (N = 1077) from 2008 to 2011.
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population (including non-vaccinated districts). Coverage
in vaccinated districts varied between 14% and 134%
(population estimated on the last demographic census
performed in 2001 explains values > 100%). The two re-
gions the most at risk, Maradi and Zinder, had vaccination
coverages of 64.2% and 80.4% respectively. However, other
regions, such as Tahoua, were barely vaccinated (13.8%)
with great variations between districts.
In 2010, in response to the epidemic due to Nm W,
509,621 doses of the trivalent PS A/C/W vaccine were dis-
tributed in the districts of Agadez, Maradi, Madarounfa,
Madaoua and Zinder with vaccination coverage varying
between 50% and 110%. An additional 1,062,577 doses of
the PS A/C vaccine were administered, including 540,640
doses for the Tahoua region, increasing the general vaccin-
ation Nm A coverage of the region to 38%. In addition to
vaccination responses, preventive vaccination campaigns
with the MenAfriVac® vaccine were organized in 2010 and
2011 as explained in the Methods section (Figure 1).
Discussion
Nm A has been the most prevalent cause of meningococ-
cal meningitis in Niger since the start of microbiological
surveillance in 1981, except in 1997 and 2006 when ser-
ogroup X [6,14] predominated. Serogroup X cases have
not reemerged in Niger although observed in large num-
bers in Burkina Faso in 2011 [15].
The incidence of Nm A declined in Niger during the
year 2010, the strain being replaced gradually by Nm W,
and meningococci of this serogroup almost disappeared
in 2011 (only five cases). This decline took place despite
the fact that only 11 of 42 districts had received the con-
jugated vaccine (corresponding to 9.9 million of a total
of 15.2 million inhabitants or 3.1 million of the 6.3 mil-
lion target population for vaccination) in 2010.
There are several potential reasons which could ac-
count for the disappearance of Nm A from the whole
country. The primary reason is likely to be the fact that
meningococcal epidemics have a natural dynamic in the
meningitis belt, as already described by Lapeyssonnie in
1963 [16], and there was a general decline in serogroup
A colonization and disease in the meningitis belt prior
to the introduction of the serogroup A conjugate vaccine
in 2010 [15]. The persistence of Nm A Sequence-Type
(ST)-7 for about 10 years in Niger (Table 2) may have
contributed to the disappearance of the serogroup A
meningococcus from the country around 2010 due to a
build-up of natural immunity to this strain across the
country during this period. Although the number of
strains typed by MLST in our study was relatively low
due to logistic constraints, and this could introduce a
bias, we believe that our MLST results provide a reason-
ably representative picture of the different ST circulating
during the epidemic seasons. Between 1995 and 1998, all
Nm A isolates from Niger typed by MLST belonged to
ST-5, from 1999 to 2001 to ST-7 (differing from ST-5
only at the pgm locus) [17], and from 2002 most of the
isolates were ST-7 [18,19]. Serogoup A meningococci
are largely clonal and all African isolates typed by the
WHO Collaborating Centers for Reference and Research
on Meningococci were remarkably homogeneous in
their PorA (P1.20,9) and FetA (F3-1) sequences [20].
Hubert et al. also observed a remarkable antigenic sta-
bility of the PorA, PorB, and FetA proteins, but with oc-
casional allelic exchange of opa genes, over years in Nm
A isolates from Ghana and Burkina Faso [21]. Ac-
cording to Bart et al. [22], serogroup A meningococci
do not persist in areas for more than a few years be-
cause they do not have the opportunity to accumulate
genetic variants indefinitely and their survival mainly
depends on geographic spread. Moreover, based on
the time separating the ST-5 from the ST-7 outbreaks
in Chad and Sudan, and the time taken for the spread
of ST-5 from East Africa to Senegal and Guinea
Bissau, Nicolas et al. [23] speculated that ST-7 might
continue to spread until 2008 to 2009; our findings
support this prediction.
Table 2 Evolution of meningococcal Sequence-type (ST)
and Clonal Complexes (cc) of serogroups A and W from
meningitis cases in Niger from 2002 to 2011
Serogroup Year ST
A 2002 ST-7 (N = 11) (cc5)
2003 ST-7 (N = 22) (cc5)
2004 ST-7 (N = 13) (cc5)
2005 ST-7 (N = 16) (cc5)
2006 ST-7 (N = 11) (cc5) and ST-5788 (N = 1) (cc5)
2007
(Nov)
ST-7 (N = 21) (cc5) and ST-2859 (N = 6) (cc5)
2008 ST-7 (N = 7) (cc5) and ST-2859 (N = 2) (cc5)
2009 ST-7 (N = 27) (cc5) and ST-2859 (N = 1) (cc5)
2010 ST-7 (N = 3) (cc5)
W 2002 ST-11 (N = 4) (cc11)
2003 ST-2881 (N = 7) (cc175) and ST-11 (N = 5)
(cc11)
2004 ST-2881 (N = 4) (cc175)
2005 ST-2881 (N = 7) (cc175)
2006 ST-2881 (N = 2) (cc175)
2007 -
2008 ST-2881 (N = 2) (cc175)
2009 -
2010 ST-11 (N = 13) (cc11)
2011 ST-11 (N = 17) (cc11)
Data are from the WHO Collaborating Center on Meningococci at Institut de
Médecine Tropicale du Service de Santé des Armées (IMTSSA), Marseille,
France before 2011 and from the Pasteur Institute, Paris, France since 2011.
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Another important factor contributing to the dis-
appearance of serogroup A cases of meningitis from
Niger may have been the massive vaccination of the
population with the PS A/C vaccine during the previous
three years, especially during the large outbreak in 2009.
There is good evidence that PS meningococcal vaccines
have little impact on carriage in the African meningitis
belt [24,25] and thus their widespread deployment is un-
likely to prevent transmission or to reduce the reservoir
of infection. However, high vaccine coverage rates will
result in a marked reduction of cases among vacci-
nated people, even if some transmission of the epi-
demic strain continues within the population. This
massive vaccination campaigns with the PS vaccine
may have contributed to the drastic decrease of Nm A
cases but this is unlikely to be the only reason. Vac-
cination with MenAfrivac®, which began in December
2010 in the 11 districts of the Western part of Niger
most affected by Nm A that year, may have helped to
reduce the transmission of Nm A, at least in this part
of the country and as found in Burkina Faso and
Chad [9,10].
Nm W has circulated in Africa for decades [26] but
rarely caused outbreaks until the large epidemic in
Burkina Faso in 2002 [27] caused by a sequence-type 11
serogroup W meningococcus, likely introduced by Hajj
pilgrims returning in 2000 from Mecca and Madina
(Saudi Arabia). In 2002-2003, molecular typing of the
sporadic meningitis cases due to Nm W in Niamey
showed two STs, ST-11 and ST-2881, the latter a new
ST differing at six of the seven MLST typing loci
(Table 2) [18]. Between 2004 and 2008, all Nm W strains
typed (N = 15) belonged to the new ST-2881. Nm W
strains of ST-11 have emerged again in Niger in 2010,
causing a small epidemic (72.2% of all meningococci)
[28]. As shown in Figure 5, the onset of epidemics due
to Nm W strains started in the HCCA of three districts,
two located at the borders with Nigeria and one located
at the border with Burkina Faso, suggesting that Nm W
strains were already present in the population and wide-
spread in Niger, making diffusion from a single point
unlikely [29]. In 2011, all Nm W strains tested were ST-
11. ST-11 Clonal complex (cc)11 is known to be a hyper-
invasive lineage which may replace the Nm A ST-7
Figure 4 Geographical extension of N. meningitidis serogroup A (Nm A) from 2008 to 2009, its decline from 2010 to 2011 and, in parallel,
the extension of Nm W in 2010 and 2011. The proportions of Nm A cases/Nm W cases per district are represented by coloured pie charts.
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lineage since the country was entirely vaccinated with
MenAfriVac® at the end of 2011. Further studies are
needed to compare the recent Nm W isolates belonging
to cc11 and those of 2002-2003 in order to understand
the reemergence of this Nm W strain.
We observed a significant difference in the age groups
of patients infected with serogroup W or A, with the
proportion of serogroup W infections being significantly
higher among young children including those under two
years of age, than among older subjects. Similarly, the at-
tack rate during the meningitis serogroup W outbreak in
Burkina Faso in 2002 was highest in patients <5 years of
age and decreased with age [27]. These findings have im-
plications regarding vaccination strategy. Currently, the
reactive outbreak response strategy with either the PS
A/C vaccine or the PS A/C/W vaccine is usually re-
stricted to those aged 2-29 years because of concerns
over the poor responsiveness of infants to polysaccharide
vaccines. Use of conjugate vaccines, which are more
immunogenic than polysaccharide vaccines in infants, in
epidemic responses would allow the whole population to
be vaccinated effectively.
Conclusions
Whereas large outbreaks of Nm A should be eliminated
by widespread deployment of the conjugate A vaccine, it
is not yet clear how the other serogroups, in particular W,
will evolve in response to this new situation. This is an im-
portant reason for strengthening surveillance in order to
detect and investigate outbreaks, to assess the dynamic of
Nm W outbreaks and to adapt the response strategy
accordingly. Finally, it is also important to monitor the
evolution and distribution of Nm of other serogroups in
order to provide information on future vaccine needs.
In the medium term, a new, affordable, multivalent
(ACWXY) conjugate vaccine may be needed as the cur-
rently available quadrivalent meningococcal conjugate
ACWY vaccines are too expensive for wide use in Africa.
Figure 5 Spatio-temporal distribution of the percentage of Nm A and Nm W in health centre catchment areas (HCCA) of Niger
between January and April 2010.
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